Sanofi Consumer Healthcare India Limited reported a 12% year-on-year revenue growth for the third quarter of fiscal year 2026, reaching ₹2,631 million. Net profit for the quarter stood at ₹1,027 million. The company also highlighted strong performance for the nine months ended September 30, 2026, with revenue from operations increasing by 16% to ₹7,280 million.
Sanofi India Reports Strong Q3’26 Financial Results
Sanofi Consumer Healthcare India Limited has announced robust financial results for the third quarter and nine months ended September 30, 2026. The company demonstrated profitable growth across its key business segments, driven by strong performance in domestic sales.
Quarterly Highlights
For the quarter ended September 30, 2026, Sanofi India reported revenue from operations of ₹2,631 million, marking a significant 12% increase compared to the same period last year. Domestic sales for the quarter grew by an impressive 19%. Profit Before Tax (PBT) saw a substantial rise of 22% year-on-year, reaching ₹1,027 million. Earnings Per Share (EPS) also grew by 22%, reflecting the increased revenue and profitability.
Nine-Month Performance
The company’s performance over the nine months ended September 30, 2026, was equally strong. Revenue from operations increased by 16% to ₹7,280 million. Domestic sales for this period grew by 15%, aided by strategic product relaunches. Export sales also saw a healthy growth of 19%. Profit Before Tax for the nine-month period was up by 24%.
Company Commentary
Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited, commented on the results, stating, “Our Q3 performance reflects the disciplined execution of our strategy and the strength of our portfolio. We delivered healthy growth, driven by volume expansion and market share gains across key brands. Our investments in brand building and expanding our distribution footprint and Healthcare Professional reach are enabling us to serve more consumers.”
Source: BSE
